Angiopoietin TIE Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Angiopoietin -TIE Growth Factor Reception pathway regulates vascular permeability and pathological vascular remodeling during inflammation, tumorigenesis, angiogenesis, and metastasis. Forming new blood vessels (angiogenesis) is an essential step in wound and tissue healing regeneration. However, angiogenesis is also an important factor for pathogenesis in conditions such as cancer and ocular neovascular disease. Increased vascular leakage from the blood vessels occurs transiently during inflammation. The unique function of the ANG-TIE pathway in vascular stabilization also makes this pathway an attractive target in sepsis, transplantation, atherosclerosis, and the vascular complications of diabetes. The ANG–TIE pathway is required for lymphatic and blood vessel improvement amid mid-gestation, and this pathway controls vascular penetrability, aggravation, and obsessive angiogenic reactions in grown-up tissues. Increased ANG2 expression has been related to a few sorts of human cancer, counting melanoma, RCC, glioblastoma, and breast and colorectal cancer (CRC) tissues. Extensive research is being conducted globally to discover new and novel molecules to be used, like bevacizumab, that is used for the treatment of many indications like Non-small Cell Lung Cancer. The development and launch of new products will thus increase the market's revenue in the forecasted years. According to the American Cancer Society 2023 report, about 85% of all lung cancers are Non-small Cell Lung Cancer (NSCLC), with an estimated 238,340 new cases of lung cancers to be diagnosed in the USA in 2023. 

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 202 products in multiple stages of clinical trials – 12 in Phase 4, 40 in Phase 3, 35 in Phase 2, and 28 in Phase 1 of the clinical trials.

Key Developments Of Angiopoietin -TIE

• In June 2022, FDA approved Beovu (brolucimab-dbll) for the treatment of Diaabetic Masculr Edema.
• In May 2020, FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in people with Hepatocellular Carcinoma.
• In December 2018, FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy for the initial treatment of Metastatic Non-squamous Non-small Cell Lung Cancer.
• In March 2018, FDA approved Lucentis (ranibizumab) 0.3mg prefilled syringe for Diabetic Macular Edema and Diabetic Retinopathy.

Approved Angiopoietin -TIE Molecules

• Avastin (bevacizumab)
• Lucentis (ranibizumab)
• Stivarga (regorafenib)
• Cabometyx (cabozantinib tablet)
• Caprelsa (vandetanib)
• Endostar (recombinant human endostatin)
• Elunate (fruquintinib)
• Cometriq (cabozantinib capsule)
• Beovu (brolucizumab-dbll)
• Lumitin (conbercept)
• Defitelio (defibrotide)
• Susvimo (ranibizumab port delivery system)

Drugs in the Pipeline of  Angiopoietin -TIE

• Iclusig (Ponatinib)
• Cometriq (Cabozantinib Capsule)
• Beovu (Brolucizumab-Dbll)
• Lumitin (Conbercept)
• Fotivda (Tivozanib)
• Sitravatinib (MGCD516)
• Trebananib (AMG 386)
• Semaxanib (SU5416)
• Carotuximab IV (ENV105)
• Defitelio (Defibrotide)
• Thrombospondin-1 Mimetic (ABT-510)
• Chiauranib (CS 2164)
• Qinlock (Ripretinib)
• Susvimo (Ranibizumab Port Delivery System)
• Byvasda (Bevacizumab Biosimilar)
• Merestinib (LY2801653)
• Hanbeitai (Bevacizumab Biosimilar)
• Pobevcy (Bevacizumab Biosimilar)
• Ofranergene Obadenovec (VB-111)
• Golvatinib (E7050)
• Imifoplatin (PT-112)
• Pegylated Endostatin (M2ES)
• E7820
• Evizon (Squalamine)
• Exherin (ADH-1)
• PAN-90806
• Dalantercept (ACE-041)
• Razuprotafib Subcutaneous (AKB-9778 SC)
• Nerofe (84AA-API 14AA)
• Zirabev (Bevacizumab-Bvzr)
• Foslinanib Immediate Release (CVM-1118)
• Isonep (Sonepcizumab)
• Nesvacumab (REGN910)
• Ankeda (Bevacizumab Biosimilar)
• Avegra (Bevacizumab Biosimilar)
• Aybintio (Bevacizumab Biosimilar)
• CDP-1 (Cetuximab Biosimilar)
• CEP-11981
• Lytenava (Bevacizumab-Vikg)
• Pravitinib (Carboxyamidotriazole Orotate)
• RBM007
• Hi-Con1 (ICON-1)
• Nesvacumab/Aflibercept Intravitreal (REGN 910-3)
• Rebastinib (DCC-2036)
• BI 695502 (Bevacizumab Biosimilar)
• CBT124 (Bevacizumab Biosimilar)
• HLX04-O (Bevacizumab Biosimilar)
• MEDI-3617
• MP0250

Clinical Activity and Developments of Angiopoietin -TIE

As of July 2023, various companies have approximately 202 products for 928 diseases. For these diseases, many trials are being conducted by players globally. For instance,

• Bay Area Retina Associates is conducting a Phase 4 clinical trial to to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema that was expected to complete by October 2022.
• In September 2021, Cairo University completed a Phase 4 clinical trial to compare the efficacy of intravitreal Ranibizumab versus Its combination with commercial Dexamethasone in The treatment of Diabetic Macular Edema.
• In December 2019, Samsung Bioepis Co., Ltd completed a Phase 3 clinical trial to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular Age-related Macular Degeneration.